BMO Capital Remains Bullish on Valeant Pharma (VRX) Following Announced Acquisition of Synergetics USA (SURG)
Tweet Send to a Friend
BMO Capital reiterated an Outperform rating and $285.00 price target on Valeant Pharmaceuticals (NYSE: VRX) following the company's announced agreement ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
